Search

Your search keyword '"Koren M"' showing total 373 results

Search Constraints

Start Over You searched for: Author "Koren M" Remove constraint Author: "Koren M"
373 results on '"Koren M"'

Search Results

1. Trends and driving forces of spring phenology of oak and beech stands in the Western Carpathians from MODIS times series 2000-2021

2. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects

3. A bark beetle infestation predictive model based on satellite data in the frame of decision support system TANABBO

4. Phenology of the beech forests in the Western Carpathians from MODIS for 2000-2015

5. Use of terrestrial laser scanning to evaluate the spatial distribution of soil disturbance by skidding operations

7. Extraction of the bare form factors for the semi-leptonic $B_s$ decays

8. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

9. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

12. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials

13. Is There Crowd Wisdom in Accounting? Evidence From Forecasts in Equity-Based Crowdfunding.

14. Risk Assessment of the Tatra Mountains Forest

15. ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia

16. Children

18. SEC Comment Letters on Firms' Use of Non-GAAP Measures: The Determinants and Firms' Responses

19. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

21. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

22. Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome

25. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

27. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

28. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

31. ILLUMINATE-A, une étude de phase 3 du lumasiran, un ARNi thérapeutique expérimental, chez les enfants et les adultes atteints d’hyperoxalurie primaire de type 1

38. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

39. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

40. Time-Series Properties of Quarterly Aggregate Earnings

41. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

42. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

43. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

45. Evolocumab and clinical outcomes in patients with cardiovascular disease

48. Institutional Trading and Abel Noser Data

Catalog

Books, media, physical & digital resources